Center for Global Health R&D Policy Assessment

With the Gates Foundation’s effort to turn the next ten years into a global “Decade of Vaccines,” vaccines have taken center stage at a number of high level policy events. On Friday, the Center for Strategic and International Studies (CSIS) hosted the “Conference on the Strategic Power of Vaccines” which brought together top leaders such as Dr.

This is a joint post with Jared Augustein.

In the years since AIDS was first identified, it has killed over 30 million individuals. The thirtieth anniversary of AIDS offers a time to reflect on these tragic losses and reevaluate how we will continue to fight this disease in the upcoming years.

Vaccines represent a remarkable set of innovations that have saved countless lives. This unwavering sense of success defined this year’s IOM Annual Meeting, “Vaccines: The Science, Policy, and Practice of Immunization.”

Did you enjoy our PDP mini-series from August? This is a guest blog post from the International AIDS Vaccine Initiative (IAVI) that gives a deeper insight on how IAVI handles IP issues.

This is the second part to our Product Development Partnership (PDP) mini-series. Here, Jennifer Woolley from Aeras discusses their PDP experience with tuberculosis vaccine development.

Tuberculosis is known as a disease of poverty.

Last month, we reported on our attendance at the Bill & Melinda Gates Foundation Product-Development Partnership (PDP) Forum “Partnering for Impact.” We discussed the role that our Center plays in this larger picture of neglected disease and global health research and development (R&D) field as well as reflected on the journey PDPs have taken and what might lie ahead for them.

Two weeks ago I traveled to Hyderabad, India, to attend the annual meeting of the Developing Country Vaccine Manufacturers Network (DCVMN).

This unusual alliance brings together vaccine companies in India, China, Brazil and a number of other mostly middle-income countries. Vaccine manufacturing in these countries is not new—many countries have long had factories, often state-owned, that produced basic vaccines for government immunization programs.